Physician profile
Christopher Nardone
NPI 1104825199
$1,277.65
in general payments reported to CMS, 2019-2025
23 companies · $53.37 in 2025
The $53.37 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2022: $91.58 · 2023: $144 · 2024: $60.30 · 2025: $53.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $214.77 | 2019-2025 | |
| Amgen INC. | $161.32 | 2019 | |
| Janssen Pharmaceuticals, INC | $160.77 | 2019 | |
| Amarin Pharma, INC. | $88.93 | 2019 | |
| Lantheus Medical Imaging, INC. | $70.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $66.24 | 2019 | |
| Gilead Sciences, INC. | $63.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $48.05 | 2019 | |
| Zoll Circulation INC | $46.58 | 2022 | |
| Abiomed | $45.51 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.08 | 2019 | |
| Baxter Healthcare | $45.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $36.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.27 | 2019 | |
| Vifor Pharma, INC. | $24.61 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $23.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.36 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.28 | 2019 | |
| Philips North America LLC | $17.59 | 2019 | |
| Abbott Laboratories | $15.03 | 2019 | |
| Medtronic, INC. | $14.79 | 2024 | Linq II |
| Smith+Nephew, INC. | $13.18 | 2019 | |
| Pfizer INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nardone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.